NR3C1 and breast cancer: This study also screened several small molecular inhibitors such as cyclooxygenase inhibitor (indoprofen, nabumetone, nimesulide, and phenacetin), ATPase inhibitor (digitoxigenin, helveticoside, ouabain), glucocorticoid receptor agonist (alclometasone, mometasone, and piretanide), which might be candidate therapeutic agents against breast cancer.